Common FDA Deficiencies in Para IV Applications: A Prevention Guide for Strategic Success
Introduction: The High-Stakes Battlefield of Generic Drug Market Entry For a pharmaceutical company, the journey to market is a strategic […]
Introduction: The High-Stakes Battlefield of Generic Drug Market Entry For a pharmaceutical company, the journey to market is a strategic […]
Executive Summary The global pharmaceutical market presents two primary avenues for investors seeking to capitalize on the expiration of brand-name
The New Mandate: Understanding China’s IP Transformation For years, the narrative surrounding intellectual property in China has been one of
Navigating the Dragon’s Den: A Definitive Guide to China’s Drug Patent Strategy Read Post »
Introduction: Why Patent Intelligence is the Cornerstone of Market Access Strategy In the high-stakes arena of the global pharmaceutical industry,
Checking Drug Patent Status: A Strategic Guide for Pharmaceutical Market Access Teams Read Post »
In pharmaceuticals no event looms larger or casts a longer shadow than the patent cliff. It is a moment of
Litigation Summary and Analysis: Bayerische Motoren Werke Aktiengesellschaft v. Onesta IP, LLC (26-1338) Executive Summary Bayerische Motoren Werke Aktiengesellschaft (BMW)
Bayerische Motoren Werke Aktiengesellschaft v. Onesta IP, LLC Read Post »
The global rare disease treatment market, a sector born from legislative incentives to address profound unmet needs, is on an
The Orphan Drug Paradox: A Strategic Playbook for Generic Entry in Rare Disease Markets Read Post »
Executive Summary: The Verdict on France’s Medical Revolution The global pharmaceutical landscape stands at the precipice of a new era,
1. The Economics of Time in Biopharma Biopharmaceutical asset valuation rests on a single, volatile variable: the duration of market
Global Exclusivity Divergence: Hatch-Waxman PTE Versus European SPC Extensions Read Post »
Get fresh news and insights, drug patent expirations & more…